Stock CONTRAVIR PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. ContraVir Pharmaceuticals Inc Nasdaq

Equities

US21234W1036

Analyst Reco.

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cantor Fitzgerald Starts Hepion Pharmaceuticals at Overweight With $3.50 Price Target
MT
HEPION PHARMACEUTICALS : Roth Capital Adjusts Price Target on Hepion Pharmaceuticals to $8 From $14, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HEPA Stock
  4. Stock
  5. News ContraVir Pharmaceuticals Inc
  6. Analyst Reco.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW